An example of such a drug is vorasidenib, which selectively inhibits only the mutated isocitrate dehydrogenase enzymes present in certain gliomas (affecting tumour growth) while sparing healthy cells that have the wild-type enzyme [62]. Here, IDH3A is linked to neoplasm.